Research and Development

Genmab says it has reached a $5 million milestone in its daratumumab collaboration with Janssen as a result of success …

Today (10th March) marks World Kidney Day 2016. Now in its 11th year, it is the largest such event focused …

US drug major Pfizer (NYSE: PFE) on Wednesday said it has entered into an accelerated share repurchase agreement with Goldman, …

The pharmaceutical industry has now contributed over £1 billion to the Department of Health towards the cost of new medicines …

Pfizer on Wednesday said late-stage trials for its drug candidate to treat haemophilia B showed prophylactic use resulted in significant reduction …

Belgian biotech firm TiGenix said the results of a 52-week follow-up study of its trial drug for a stem-cell condition …

 It has been announced that Karl-Ludwig Kley, chief executive officer at Merck, will step down from his position at the …

A report into the clinical trial tragedy in France in January has called the event “astonishing and unprecedented” but did …

Specialist pharma company Ipsen is partnering with French start-up PeptiMimesis to develop and market of novel therapeutic peptides in oncology. …

Crown Bioscience has announced the acquisition of PreClinOmics, which will see the US-based drug discovery solutions company expand its cardiovascular …

The Dementia Consortium has welcomed MSD into the fold as a new partner in its global venture to accelerate drug …

AstraZeneca’s biologics R&D arm MedImmune has been granted Orphan Drug Designation by the FDA for its investigational anti-CD19 monoclonal antibody, …

Danish drug-company Genmab (Nasdaq Copenhagen: GEN) said it will discontinue the late-stage trials for Arzerra (ofatumumab) to develop a treatment for …

UK drug major AstraZeneca (LSE: ANZ) said its biologics R&D unit, MedImmune, has received Fast Track designation from the US …

The pharmaceuticals division at German-based Bayer will collaborate with the renowned medicinal chemistry and biology departments at the Universities of …